Author

V. Adema

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Approach:genetic perturbation / CRISPR· 2

Frequent Co-Authors

F. Ma· 4 shared G. Garcia-Manero· 4 shared G. Montalban-Bravo· 4 shared I. Ganan-Gomez· 4 shared S. Colla· 4 shared N. Thongon· 3 shared R. Kanagal-Shamanna· 3 shared B. Wildeman· 2 shared

Activity by Year

2023-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

F. Ma

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

V. Adema, I. Ganan-Gomez, F. Ma, J. J. Rodriguez-Sevilla, K. Chien, H. Yang, N. Thongon, R. Kanagal-Shamanna, S. Loghavi, G. Montalban-Bravo, D. Hammond, Y. Gu, R. Tan, L. Tan, P. Lorenzi, , S. Colla

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

bioRxiv · Sep 28, 2023 · PreprintCancer Biology

Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic Syndromes

J. J. Rodriguez Sevilla, I. Ganan-Gomez, F. Ma, K. Chien, G. Montalban-Bravo, R. Kanagal-Shamanna, S. Loghavi, V. Adema, A. Bazinet, G. Garcia-Manero, S. Colla

This study shows MDS hematopoietic stem cells reprogram their differentiation state to bypass venetoclax sensitivity through genetic mutations and transcriptional changes.

bioRxiv · Sep 25, 2023 · PreprintCancer Biology

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia

G. Montalban-Bravo, F. Ma, N. Thongon, H. Yang, I. Ganan-Gomez, J. J. Rodriguez-Sevilla, V. Adema, B. Wildeman, P. P. Lockyer, Y. J. Kim, T. Tanaka, F. Darbaniyan, S. Pancholy, G. Zhang, G. Al-Atrash, , S. Colla

This study identifies MCL1 as a survival factor in RAS-mutated CMML, explaining resistance to BCL2 inhibitors and suggesting new therapeutic targets.

bioRxiv · Apr 7, 2023 · PreprintCancer Biology

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

N. Thongon, F. Ma, P. Lockyer, N. Baran, J. Liu, C. Jackson, A. Rose, B. Wildeman, M. Marchesini, V. Marchica, P. Storti, N. Giuliani, I. Ganan-Gomez, V. Adema, Y. Qing, , S. Colla

This study identifies DNA2 as a key factor in mitochondrial metabolism that enables multiple myeloma cells to survive DNA damage, showing that targeting DNA2 overcomes metabolic reprogramming and enhances therapy effectiveness.

bioRxiv · Feb 22, 2023Cancer Biology